Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors

被引：25

作者：

Vaduganathan, Muthiah ^{[1
]}

Januzzi, James L., Jr. ^{[2
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA

[2] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2019年 / 124卷

关键词：

CARDIOVASCULAR OUTCOMES; LOWERING THERAPIES; RISK-FACTORS; EMPAGLIFLOZIN; MORTALITY; DESIGN; BURDEN; ADULTS;

D O I：

10.1016/j.amjcard.2019.10.026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure is a common complication among patients with type 2 diabetes mellitus and is associated with significantly increased risks of subsequent morbidity and mortality. Until recently, therapies and strategies were lacking to attenuate this excess risk of heart failure in this population. Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent a unique class of glucose-lowering therapies that have multisystem health benefits. Three large cardiovascular outcomes trials have demonstrated consistent reductions in heart failure events among patients with type 2 diabetes mellitus with, or at risk for, atherosclerotic cardiovascular disease. Another trial recently showed that an SGLT2 inhibitor, canagliflozin, also significantly reduced heart failure events among patients with type 2 diabetes mellitus and albuminuric chronic kidney disease. The SGLT2 inhibitor class represents an important new therapeutic approach for the prevention of heart failure in at-risk patients with type 2 diabetes mellitus, and is actively being studied for use in treating patients with heart failure (with or without type 2 diabetes mellitus). (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：S20 / S27

页数：8

共 36 条

[1]

[Anonymous], 2018, DIABETES CARE S1, DOI DOI 10.2337/DC18-S008

[2] The Population Burden of Heart Failure Attributable to Modifiable Risk Factors The ARIC (Atherosclerosis Risk in Communities) Study [J].

Avery, Christy L. ;

Loehr, Laura R. ;

Baggett, Christopher ;

Chang, Patricia P. ;

Kucharska-Newton, Anna M. ;

Matsushita, Kunihiro ;

Rosamond, Wayne D. ;

Heiss, Gerardo .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) :1640-1646

[3] Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030 [J].

Bommer, Christian ;

Sagalova, Vera ;

Heesemann, Esther ;

Manne-Goehler, Jennifer ;

Atun, Rifat ;

Baernighausen, Till ;

Davies, Justine ;

Vollmer, Sebastian .

DIABETES CARE, 2018, 41 (05) :963-970

[4] The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors [J].

Butler, Javed ;

Hamo, Carine E. ;

Filippatos, Gerasimos ;

Pocock, Stuart J. ;

Bernstein, Richard A. ;

Brueckmann, Martina ;

Cheung, Alfred K. ;

George, Jyothis T. ;

Green, Jennifer B. ;

Januzzi, James L. ;

Kaul, Sanjay ;

Lam, Carolyn S. P. ;

Lip, Gregory Y. H. ;

Marx, Nikolaus ;

McCullough, Peter A. ;

Mehta, Cyrus R. ;

Ponikowski, Piotr ;

Rosenstock, Julio ;

Sattar, Naveed ;

Salsali, Afshin ;

Scirica, Benjamin M. ;

Shah, Sanjiv J. ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Wanner, Christoph ;

Woerle, Hans-Juergan ;

Zannad, Faiez ;

Anker, Stefan D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 (11) :1390-1400

[5] Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV) [J].

Cannon, Christopher P. ;

Mcguire, Darren K. ;

Pratley, Richard ;

Dagogo-Jack, Sam ;

Mancuso, James ;

Huyck, Susan ;

Charbonnel, Bernard ;

Shih, Weichung J. ;

Gallo, Silvina ;

Masiukiewicz, Urszula ;

Golm, Gregory ;

Cosentino, Francesco ;

Lauring, Brett ;

Terra, Steven G. .

AMERICAN HEART JOURNAL, 2018, 206 :11-23

[6] Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis [J].

Castagno, Davide ;

Baird-Gunning, Jonathan ;

Jhund, Pardeep S. ;

Biondi-Zoccai, Giuseppe ;

MacDonald, Michael R. ;

Petrie, Mark C. ;

Gaita, Fiorenzo ;

McMurray, John J. V. .

AMERICAN HEART JOURNAL, 2011, 162 (05) :938-948.e2

[7] 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease [J].

Das, Sandeep R. ;

Everett, Brendan M. ;

Birtcher, Kim K. ;

Brown, Jenifer M. ;

Cefalu, William T. ;

Januzzi, James L., Jr. ;

Kalyani, Rita Rastogi ;

Kosiborod, Mikhail ;

Magwire, Melissa L. ;

Morris, Pamela B. ;

Sperling, Laurence S. ;

Ahmad, Tariq ;

Hucker, William ;

Kumbhani, Dharam J. ;

Marine, Joseph E. ;

Piana, Robert N. ;

Rao, Sunil V. ;

Scherrer-Crosbie, Marielle ;

Watson, Karol E. ;

Wiggins, Barbara S. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (24) :3200-3223

[8]

Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI [10.2337/dci18-0033, 10.1007/s00125-018-4729-5]

[9] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Butler, Javed ;

van de Borne, Philippe ;

Zinman, Bernard ;

Lachin, John M. ;

Wanner, Christoph ;

Woerle, Hans J. ;

Hantel, Stefan ;

George, Jyothis T. ;

Johansen, Odd Erik ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. .

EUROPEAN HEART JOURNAL, 2018, 39 (05) :363-370

[10] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

← 1 2 3 4 →